Dynavax Technologies Co. (NASDAQ:DVAX) insider David F. Novack sold 16,109 shares of the stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $16.30, for a total value of $262,576.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of Dynavax Technologies Co. (NASDAQ:DVAX) traded down $0.05 during mid-day trading on Friday, reaching $16.40. The company’s stock had a trading volume of 2,159,912 shares, compared to its average volume of 1,310,532. Dynavax Technologies Co. has a one year low of $5.00 and a one year high of $24.45. The firm has a market capitalization of $1,014.65, a P/E ratio of -8.91 and a beta of 1.05.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.32). Dynavax Technologies had a negative net margin of 29,099.08% and a negative return on equity of 57.43%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.53 million. analysts expect that Dynavax Technologies Co. will post -1.91 earnings per share for the current year.
A number of research firms recently commented on DVAX. Cantor Fitzgerald restated an “overweight” rating and issued a $27.00 price objective (up previously from $25.00) on shares of Dynavax Technologies in a report on Thursday, March 8th. Royal Bank of Canada restated a “buy” rating and issued a $25.00 price objective on shares of Dynavax Technologies in a report on Friday, March 9th. BidaskClub downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. Cowen restated a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a report on Wednesday, February 21st. Finally, Zacks Investment Research downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $24.67.
A number of hedge funds have recently made changes to their positions in DVAX. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Dynavax Technologies by 474.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 5,880 shares during the last quarter. Royal Bank of Canada grew its holdings in Dynavax Technologies by 17.0% during the second quarter. Royal Bank of Canada now owns 20,454 shares of the biopharmaceutical company’s stock valued at $198,000 after purchasing an additional 2,975 shares during the last quarter. Voya Investment Management LLC grew its holdings in Dynavax Technologies by 26.3% during the second quarter. Voya Investment Management LLC now owns 21,403 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 4,462 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in Dynavax Technologies during the fourth quarter valued at approximately $257,000. Finally, SG Americas Securities LLC acquired a new position in Dynavax Technologies during the third quarter valued at approximately $287,000. Institutional investors own 72.52% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Dynavax Technologies Co. (DVAX) Insider David F. Novack Sells 16,109 Shares” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/03/17/dynavax-technologies-co-dvax-insider-david-f-novack-sells-16109-shares.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.